NOVATARG has pioneered a novel nonequilibrium imaging approach to solve the structures of difficult membrane proteins involved in a wide range of serious and life-threatening diseases, including cancer, diabetes, autoimmune, cardiovascular and neurodegenerative diseases, psychiatric disorders, as well as infectious diseases like HIV/AIDS and COVID-19.
We are working to drastically improve the speed at which membrane protein targets and therapeutics are identified, the specificity of target engagement, and the cost of identifying and developing clinical candidates.
NOVATARG’s nonequilibrium imaging approach holds potential to fundamentally shift the current landscape of therapeutic development. It aims to address crucial unmet needs in modern membrane protein structure-based drug design (SBDD) by -for innovative targeted biomedicines and therapeutics.
Membrane proteins are the largest class of drug targets. The market for drugs targeting membrane proteins is estimated to exceed 1 trillion U.S. dollars.
However, the lack of solubility of membrane proteins in water together with their dependence on lipids has imposed critical bottlenecks to characterization of the structures of membrane proteins, which is indispensable to modern structure-based drug design (SBDD) efforts. Conventional solution-based techniques often fail, or produce unreliable, inconsistent, or insufficient structural information for membrane proteins.
NOVATARG holds licenses to patented technologies demonstrating the company’s unique potential to streamline biomedical research and drug discovery advancements.